Drug discovery and mental illness
Author(s) -
Barry D. Lebowitz,
H. William Harris
Publication year - 2002
Publication title -
dialogues in clinical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.11
H-Index - 87
eISSN - 1958-5969
pISSN - 1294-8322
DOI - 10.31887/dcns.2002.4.4/blebowitz
Subject(s) - mental illness , mechanism (biology) , paradigm shift , psychiatry , drug development , drug discovery , clinical trial , psychology , medicine , drug , mental health , bioinformatics , biology , philosophy , epistemology , pathology
Mental disorders are among the most disabling of all diseases. Effective well-documented medications have been available for many decades. Yet, limited understanding of the pathophysiology of mental disorders has impeded the development of novel treatments. Drug discovery must move toward a net* mechanism-based paradigm using the tools of contemporary genetic and molecular medicine. At the same time, this new paradigm must be matched by an equivalent effort to modernize established approaches to clinical trials methodology.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom